Patients with a certain type of lung cancer — stage II to IIIB non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation — saw better results when treated with the ...

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically ...

The Trop-2 protein is highly expressed in EGFR -mutated NSCLC, and resistance to EGFR TKIs such as osimertinib is associated ...

Adding osimertinib to platinum-based chemotherapy may improve outcomes in patients with EGFR-mutant, advanced NSCLC who had disease progression on first-line osimertinib.

How Well Does Tagrisso Work for Lung Cancer? The FDA approved Tagrisso based on clinical trials for EGFR-mutated lung cancer in several different scenarios. Tagrisso was studied in people who had lung ...

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and ...

Combining osimertinib with LCT significantly improved PFS in metastatic EGFR-mutant NSCLC, reducing disease progression risk by 34%. The trial showed enhanced PFS across different EGFR mutation ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...

Positive results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

RYBREVANT® combination extends survival and significantly reduces common EGFR and MET resistance mutations seen with osimertinib-based treatment "Choosing the first treatment for EGFR-mutated NSCLC is ...

"The survival curve tells a clear story. RYBREVANT plus LAZCLUZE helps patients live longer, and the benefit keeps growing over time," said trial investigator Professor Nicolas Girard*, M.D., Ph.D., ...